

REFERENCE

- Arnold, R. J. G. (2021) *Pharmacoeconomics From Theory to Practice Second Edition, CRC PRESS.*
- Bozkurt, B. *et al.* (2021) ‘Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition o’, *European Journal of Heart Failure*, 23(3), pp. 352–380.
- Buddeke, J. *et al.* (2019) ‘Comorbidity in patients with cardiovascular disease in primary care : a cohort study with routine healthcare data’, (June).
- Davison, B. A. *et al.* (2016) ‘Patient journey after admission for acute heart failure: length of stay, 30-day readmission and 90-day mortality’, *European Journal of Heart Failure*, 18(8), pp. 1041–1050. doi: 10.1002/ejhf.540.
- Dipiro, J. T. *et al.* (2015) *Pharmacotherapy A Pathophysiologic Approach, United State: McGraw-Hill Education.*
- Direktorat Jenderal Bina Kefarmasian dan Alat Kesehatan, K. K. R. I. (2013) *Pedoman Penerapan Kajian Farmakoekonomi, kementrian kesehatan republik indonesia.* Edited by A. dr. Z. F. Drs. Prih Sarnianto, M.Sc and M. Erie Gusnellyanti, S.Si, Apt. Jakarta.
- Farooqui, N. *et al.* (2024) ‘Advanced Heart Failure Characteristics and Outcomes in Women and Men’, *Journal of the American Heart Association*, 13(13), pp. 1–12. doi: 10.1161/JAHA.123.033374.
- Heidenreich, P. A. *et al.* (2022a) *2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines, Circulation.*
- Heidenreich, P. A. *et al.* (2022b) *2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines, Circulation.* doi: 10.1161/CIR.0000000000001063.
- Karaban, K. *et al.* (2024) ‘Coagulation Disorders and Thrombotic Complications in

- Heart Failure With Preserved Ejection Fraction', *Current Problems in Cardiology*, 49(1). doi: 10.1016/j.cpcardiol.2023.102127.
- Kemenkes RI (2021) 'Pedoman Nasional Pelayanan Kedokteran Tata Laksana Gagal Jantung', *Keputusan Menteri Kesehatan Republik Indonesia Nomor Hk.01.07/Menkes/4801/2021*, pp. 1–6. Available at: <https://kemkes.go.id/id/pnpk-2021---tata-laksana-gagal-jantung>.
- Kumalasari, N. D. *et al.* (2019) 'Direct Medical Cost Analysis Among Coronary Heart Disease and Heart Failure Outpatients at One Hospital', *JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice)*, 9(2), pp. 55–64. doi: 10.22146/jmpf.38170.
- Lahewala, S. *et al.* (2019) 'Heart failure: Same-hospital vs. different-hospital readmission outcomes', *International Journal of Cardiology*, 278, pp. 186–191. doi: 10.1016/j.ijcard.2018.12.043.
- Lala, A. *et al.* (2022) 'Sex Differences in Heart Failure', *Journal of Cardiac Failure*, 28(3), pp. 477–498. doi: 10.1016/j.cardfail.2021.10.006.
- Levine, R. A. *et al.* (2015) 'Mitral valve disease--morphology and mechanisms.', *Nature reviews. Cardiology*, 12(12), pp. 689–710. doi: 10.1038/nrcardio.2015.161.
- Mangunkusumo, R. C. (2024) 'Faktor-Faktor yang Memengaruhi Kualitas Hidup Pasien Gagal Jantung Kronik Fraksi Ejeksi Terjaga (HFpEF) Rawat Jalan di RSUPN Dr. Cipto Mangunkusumo', *Jurnal Penyakit Dalam Indonesia*, 11(1).
- Marc Thiriet (2018) *Vasculopathies*, Springer International Publishing AG.
- Martin, S. S. *et al.* (2024) *2024 Heart Disease and Stroke Statistics: A Report of US and Global Data from the American Heart Association*, *Circulation*.
- Masarone, D. *et al.* (2017) 'Management of arrhythmias in heart failure', *Journal of Cardiovascular Development and Disease*, 4(1). doi: 10.3390/jcdd4010003.
- Page, R. L. *et al.* (2016) *Drugs that may cause or exacerbate heart failure*, *Circulation*. doi: 10.1161/CIR.0000000000000426.
- Perhimpunan Kedokteran Spesialis Kardiovaskular Indonesia (2023) *Pedoman*

Tatalaksana Gagal Jantung, PERKI.

- Rascati, K. L. (2014) 'Essentials of Pharmacoeconomic Second Edition', *Lippincott Williams & Wilkins, a Wolters Kluwer business*.
- Ruiz-García, A. *et al.* (2023) 'Heart Failure Prevalence Rates and Its Association with Other Cardiovascular Diseases and Chronic Kidney Disease: SIMETAP-HF Study', *Journal of Clinical Medicine*, 12(15), pp. 1–13. doi: 10.3390/jcm12154924.
- Shahim, B. *et al.* (2023) 'Global Public Health Burden of Heart Failure: An Updated Review', *Cardiac Failure Review*, 9(Icd). doi: 10.15420/cfr.2023.05.
- Shuvy, M. *et al.* (2020) 'The age-adjusted Charlson comorbidity index: A significant predictor of clinical outcome in patients with heart failure', *European Journal of Internal Medicine*, 73(January), pp. 103–104. doi: 10.1016/j.ejim.2019.12.030.
- Sotomi, Y. *et al.* (2021) 'Sex differences in heart failure with preserved ejection fraction', *Journal of the American Heart Association*, 10(5), pp. 1–20. doi: 10.1161/JAHA.120.018574.
- Sulita, H. (2011) *Analisis Biaya Dan Variabel Yang Berpengaruh Terhadap Biaya Pengobatan Pasien Gagal Jantung Rawat Inap Di RSUD Sleman Yogyakarta Periode Tahun 2009*. Universitas Gadjah Mada.
- Syafriah, W. O. (2018) 'Analisis Biaya Pengobatan Gagal Jantung pada Pasien Rawat Inap di RSUD Kabupaten Karanganyar Tahun 2011-2012', *Pharmauho: Jurnal Farmasi, Sains, dan Kesehatan*, 4(1), pp. 48–56.
- Di Tanna, G. L. *et al.* (2019) *Evaluating Cost-Effectiveness Models for Pharmacologic Interventions in Adults with Heart Failure: A Systematic Literature Review*, *Pharmacoeconomics*. Springer International Publishing. doi: 10.1007/s40273-018-0755-x.
- Tjandrawinata, R. R. (2016) 'Peranan Farmakoekonomi dalam Penentuan Kebijakan yang Berkaitan dengan Obat-Obatan. In Working Paper of Dexa Medica Group (Issue January 2016)'.
- Tonin, F. S. *et al.* (2021) 'Principles of pharmacoeconomic analysis: The case of pharmacist-led interventions', *Pharmacy Practice*, 19(1), pp. 1–10.

- Urbich, M. *et al.* (2020) 'A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014–2020)', *PharmacoEconomics*, 38(11), pp. 1219–1236.
- Virani, S. S. *et al.* (2021) *Heart Disease and Stroke Statistics - 2021 Update: A Report From the American Heart Association*, *Circulation*.
- Viviandhari, D. (2009) *Analisis Biaya Pasien Gagal Jantung Rawat Inap RSUD Dr. Moewardi Surakarta Periode tahun 2008*. Universitas Gadjah Mada.
- Watson, R. D. S., Gibbs, C. R. and Lip, G. Y. H. (2000) 'ABC of heart failure: Clinical features and complications', *British Medical Journal*, 320(7229), pp. 236–239. doi: 10.1136/bmj.320.7229.236.
- WHO (2020) *Non-Communicable Diseases Progress Monitor 2020*, *World Health*.
- Ziaeeian, B. and Fonarow, G. C. (2016) 'Epidemiology and aetiology of heart failure', *Nature Reviews Cardiology*, 13(6), pp. 368–378.